By SPC News Staff
The FDA lowered the age for voxelotor (Oxbryta, Global Blood Therapeutics) to treat sickle cell disease (SCD) to children as young as 4 years old.
The FDA also approved a separate New Drug Application for voxelotor tablets for oral suspension: a new dispersible, once-daily tablet dosage form suitable for young patients, as well as for older patients with difficulty swallowing whole tablets. Voxelotor is the first FDA-approved treatment for children with SCD that directly